The company’s approach to retinal degeneration arrives as the FDA and China’s National Medical Products Administration simultaneously cleared the therapy for testing. NouvSight001, which previously secured FDA Orphan Drug Designation in 2024, is now slated for Phase I/III studies in China and Phase I/II trials in the United States. Unlike existing treatments restricted to specific genetic mutations, this cell replacement therapy targets a broader range of patients suffering from the progressive loss of vision.
iRegene Therapeutics Cleared for Retinitis Pigmentosa Trials
Regulators in the U.S. and China have greenlit clinical trials for NouvSight001, an off-the-shelf photoreceptor cell therapy developed by iRegene Therapeutics. Designed to treat retinitis pigmentosa, the therapy utilizes a proprietary AI and chemical induction platform to bypass the need for specific patient genotypes, offering a potential breakthrough for millions.
This development highlights the scalability of iRegene’s underlying "AI + Chem" platform, which uses small molecules to control cell fate. By standardizing manufacturing for allogeneic, off-the-shelf therapies, the firm aims to address the structural burden of aging-related diseases. According to Chief Financial Officer Tianshi Ruan, the company is leveraging its earlier experience with Parkinson’s disease programs to synchronize clinical execution across international regulatory frameworks, focusing on global multicenter studies and future commercial partnerships.
Comments (0)
No comments yet. Be the first!